Randomized-Controlled Trial to Compare the Efficacy of Andrographis paniculata Powder and Favipiravir for the Treatment of Mild COVID-19

Puriwatthanapong et al., Journal of Thai Traditional & Alternative Medicine, 21:3

Dec 2023

Source PDF All Studies Meta AnalysisMeta

RCT 231 mild COVID-19 outpatients in Thailand comparing Andrographis paniculata (AP) extract in two forms versus favipiravir, showing no significant differences between groups. Patients were randomized to either aerial parts AP extract (n=77), AP leaf extract (n=77), or favipiravir (n=77) for 5 days. There was no control group. There were no significant differences between groups in progression to pneumonia, clinical severity changes, or viral clearance at days 5 and 10. Authors suggest that AP extracts may be as effective as favipiravir for mild COVID-19 and note AP's lower cost.

Potential risks of favipiravir include the creation of dangerous variants, and mutagenicity, carcinogenicity, teratogenicity, and embryotoxicity1-5.

Important missing comments or errors? Let us know.

Study covers andrographolide and favipiravir.

1. Zhirnov et al., Favipiravir: the hidden threat of mutagenic action, Journal of microbiology, epidemiology and immunobiology, doi:10.36233/0372-9311-114.elpub.ru, doi.org.

2. Waters et al., Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of molnupiravir, Environmental and Molecular Mutagenesis, doi:10.1002/em.22471.wiley.com, doi.org.

3. Hadj Hassine et al., Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity, Viruses, doi:10.3390/v14040841.mdpi.com, doi.org.

4. Shum, C., An investigational study into the drug-associated mutational signature in SARS-CoV-2 viruses, The University of Hong Kong, PhD Thesis, hub.hku.hk/handle/10722/344396.hku.hk.

5. Shiraki et al., Convenient screening of the reproductive toxicity of favipiravir and antiviral drugs in Caenorhabditis elegans, Heliyon, doi:10.1016/j.heliyon.2024.e35331.sciencedirect.com, doi.org.

Puriwatthanapong et al., 29 Dec 2023, Randomized Controlled Trial, Thailand, peer-reviewed, 14 authors.

This Paper Favipiravir All

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0